赛默飞（PPD）：2026年全球医药研发动向报告：150位行业领导者洞见（英文版）-三个皮匠报告

1、BALANCINGBALANCINGPRESSURE AND POSSIBILITYThe Pulse 2026Global R&D insights in pharmaceuticalsMethodology 4 Executive summary 8Detailed findings:Challenges,strategies and state of the industry 15Detailed findings:Patient-focused strategies 24Detailed findings:AI/ML in clinical development 28Detailed

2、 findings:Outsourcing 32Appendix 34Contents2The Pulse About The PulseThe future for drug developers is increasingly shaped by their ability to adopt innovative strategies and new technologies while navigating an environment marked by complexity and rapid change.Thats why the PPD clinical research bu

3、siness of Thermo Fisher Scientific surveyed 150 leaders at biotech and pharmaceutical organizations around the globe to assess trends in drug discovery and development.Respondents shared barriers to bringing drugs to market,innovations influencing progress,and perspectives on topics such as AI,patie

4、nt recruitment,the regulatory landscape and more.Now in its fourth year,The Pulse reveals a stark throughline:uncertainty has become the dominant backdrop for drug development.Many of the past years shifts economic pressures,evolving care models,regulatory recalibration and rising expectations to do

5、 more with less continue to reverberate.As companies shore up investments and reassess their portfolios,leaders are grappling with immense pressure to deliver in an environment where the ground keeps moving.Across this years data,a clear picture emerges.Drug developers are navigating shifting sands:

6、balancing long-term scientific ambition with short-term operational realities,confronting challenges that are becoming more intertwined and less predictable,and working to maintain momentum despite forces largely outside their control.The Pulse goes beyond the numbers to explore what this pervasive

赛默飞（PPD）：2026年全球医药研发动向报告：150位行业领导者洞见（英文版）（40页）.pdf

相关报告